Article ID Journal Published Year Pages File Type
10587921 Bioorganic & Medicinal Chemistry Letters 2013 4 Pages PDF
Abstract
The neonatal Fc receptor, FcRn, prolongs the half-life of IgG in the serum and represents a potential therapeutic target for the treatment of autoimmune disease. Small molecules that block the protein-protein interactions of human IgG-human FcRn may lower pathogenic autoantibodies and provide effective treatment. A novel class of quinoxalines has been discovered as antagonists of the IgG:FcRn protein-protein interaction through optimization of a hit derived from a virtual ligand-based screen.
Related Topics
Physical Sciences and Engineering Chemistry Organic Chemistry
Authors
, , ,